Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

Bavarian Nordic experienced significant growth in 2025, primarily driven by its Travel Health and Public Preparedness segments. The Travel Health sector benefited from increased demand for rabies and TBE vaccines, with the chikungunya vaccine (VIMKUNYA®) contributing DKK 85 million in its first year. The Public Preparedness segment saw a surge in demand for mpox vaccines.

However, the company anticipates a normalization in Public Preparedness revenues in 2026. The end of partnerships with Valneva and Dynavax will also impact revenue. Despite these changes, Bavarian Nordic expects continued growth in Travel Health, with a focus on expanding its portfolio. R&D efforts will prioritize life-cycle management and advancing early-stage pipeline assets.

The strong performance was primarily driven by the Travel Health and Public Preparedness sectors, with increased demand for rabies, TBE, and mpox vaccines.

Bavarian Nordic expects revenue of DKK 5,000 – 5,200 million and an EBITDA margin of approximately 25% for 2026.

R&D spending will prioritize life-cycle management of the commercial portfolio and the advancement of early-stage pipeline assets.

Do you think Bavarian Nordic will maintain its growth trajectory in the coming years? Share this article with others who need to stay ahead of this trend!